financetom
Business
financetom
/
Business
/
Plurilock Q2 Loss Widens, But Revenue up
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Plurilock Q2 Loss Widens, But Revenue up
Sep 1, 2024 1:15 AM

10:45 AM EDT, 08/30/2024 (MT Newswires) -- Plurilock Security ( PLCKF ) , a global cybersecurity services and solutions provider, reported Friday a wider second quarter net loss even though revenue rose slightly.

Net loss rose to near $3.914 million, or $0.11 per basic and diluted share, from near $2.6 million, or $0.29 per share, last year.

But revenue increased slightly, from $12.25 million, to $12.642 million, with 98% Critical Services growth to $1.45 million in Q2 2024 from $0.73 million in Q2 2023.

Adjusted EBITDA improved to a loss of $591,888 in Q2 2024 from a loss of $1,870,054 in Q2 2023 from stronger margins and cost management versus the prior year.

"In the second quarter of 2024, Plurilock continued to expand its Service offerings, a key strategic focus of our growth and margin expansion strategies," said Ian Paterson, CEO of Plurilock. "Throughout the quarter and post June 30, 2024, we continued to add new clients and expand our presence within existing clients. Our pipeline of opportunities remains strong; our high-margin Critical Services is scaling nicely; and our business transformation remains on schedule. We will continue to prioritize its high-end cyber consulting business to generate higher gross margins and accelerate our path to profitability."

Plurilock was last seen down $0.10, to $0.85 on the TSX Venture Exchange.

Price: 0.87, Change: -0.08, Percent Change: -8.42

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FDA extends review of Ascendis Pharma's hormone disorder therapy
FDA extends review of Ascendis Pharma's hormone disorder therapy
May 14, 2024
May 14 (Reuters) - The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's ( ASND ) therapy to treat adult patients with a hormone disorder, the company said on Tuesday. The FDA is now set to make its decision known by Aug. 14, compared to its previous action date set for May 14. ...
Coinbase Global Resolves System-Wide Outage
Coinbase Global Resolves System-Wide Outage
May 14, 2024
02:38 PM EDT, 05/14/2024 (MT Newswires) -- Coinbase Global ( COIN ) said Tuesday that it resolved a system-wide outage that affected several programming interfaces. The company reported the outage late Monday with the assurance that all funds are safe. The outage lasted about three hours, according to the timeline on the company's incident reports page. Coinbase shares were up...
Coca Cola Insider Sold Shares Worth $561,801, According to a Recent SEC Filing
Coca Cola Insider Sold Shares Worth $561,801, According to a Recent SEC Filing
May 14, 2024
02:35 PM EDT, 05/14/2024 (MT Newswires) -- Monica Howard Douglas, Executive Vice President, on May 10, 2024, sold 8,874 shares in Coca Cola (KO) for $561,801. Following the Form 4 filing with the SEC, Douglas has control over a total of 40,038 shares of the company, with 33,638 shares held directly and 6,400 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/21344/000112760224015229/xslF345X03/form4.xml Price: 63.01,...
Ferrari Prices Notes Offering Due May 2030
Ferrari Prices Notes Offering Due May 2030
May 14, 2024
02:39 PM EDT, 05/14/2024 (MT Newswires) -- Ferrari ( RACE ) said Tuesday it has priced its offering of 500 million euros ($541.1 million) of notes due in May 2030 at 99.677% of the principal amount. The company said the notes have a fixed annual coupon of 3.625%. Ferrari ( RACE ) said it will use the proceeds for general...
Copyright 2023-2025 - www.financetom.com All Rights Reserved